Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review

Schaefer, Lauren; Comfere, Nneka I.; Sokumbi, Olayemi

doi:10.1007/s40257-022-00749-1

Cited by 9 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this review, we have summarized a total of 28 cases (including 1 new case from the senior author's practice) that have a temporal association with the development of MF/CTCL, a mean time of 18.5 weeks on dupilumab therapy. Park et al and Schaefer et al have recently reviewed MF/CTCL in association with dupilumab or other biologic therapies [30,31], but these series did not apply stringent criteria of at least 6 weeks of dupilumab exposure as we have to underscore meaningful exposure to this agent in association with the evolution of MF/CTCL. Heymann's commentary highlighted new reports of dupilumab in prurigo nodularis and bullous pemphigoid that appeared in the same journal issue as that of Espinosa et al [32], who reported 3 cases of AD developing MF while on dupilumab as well as 3 cases of MF who received it as adjuvant therapy for itching [12].…”

Section: Discussionmentioning

confidence: 99%

Mycosis Fungoides Presenting After Dupilumab Therapy: Case Report and Systematic Review

Fivenson¹

2023

J Clin Investig Dermatol

View full text Add to dashboard Cite

Inviting InnovationsWhile the etiology of MF remains unknown, various hypotheses have been proposed which include genetic, environmental, infectious, and autoimmune involvement [4,5]. Recently, there have been several reports of MF diagnosed after the initiation of dupilumab therapy for atopic dermatitis (AD) or other eczematous conditions [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]. In this report, we present another case of AD developing stage IIB MF in the ensuing months after starting dupilumab and a systematic review of all published cases of this association, as well as the hypotheses for how this transition may occur. MethodsA systematic English language literature review using PubMed and Google Scholar between January 2021 and March 2023, with key words of (mycosis fungoides and dupilumab, cutaneous T cell lymphoma and dupilumab, as well as descriptors of transformation, progression and misdiagnosis) was conducted to identify reports of the diagnosis of MF/CTCL in association with dupilumab treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Mycosis Fungoides Presenting After Dupilumab Therapy: Case Report and Systematic Review

Fivenson¹

2023

J Clin Investig Dermatol

View full text Add to dashboard Cite

show abstract

“…Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of T-cell malignancies that specifically affect the skin and present as plaques, papules, or masses, with mycosis fungoides (MF) and Sézary syndrome (SS) as the most common subtypes, accounting for 60–70% of all CTCL cases [ 5 ]. These tumor cells primarily accumulate in the skin but may metastasize to the blood and other organs in advanced stages, often leading to resistance to chemotherapy.…”

Section: Overview Of T-cell Malignanciesmentioning

confidence: 99%

Advances in CAR-T-cell therapy in T-cell malignancies

Zheng,

Zhu,

Xiao

2024

J Hematol Oncol

View full text Add to dashboard Cite

Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of aggressive T-cell malignancies. This article reviews the challenges of CAR-T-cell therapy in treating T-cell malignancies and summarizes the progress of preclinical and clinical studies in this area. We present an analysis of clinical trials of CAR-T-cell therapies for the treatment of T-cell malignancies grouped by target antigen classification. Moreover, this review focuses on the major challenges encountered by CAR-T-cell therapies, including the nonspecific killing due to T-cell target antigen sharing and contamination with cell products during preparation. This review discusses strategies to overcome these challenges, presenting novel therapeutic approaches that could enhance the efficacy and applicability of CAR-T-cell therapy in the treatment of T-cell malignancies. These ideas and strategies provide important information for future studies to promote the further development and application of CAR-T-cell therapy in this field.

show abstract

“…In such instances, the primary benefit of early MF detection is providing opportunities to initiate appropriate MF treatment early in the disease course. This also prevents MF patients from receiving inappropriate treatments such as cyclosporine, TNF-alpha inhibitors, and dupilumab that may instigate MF progression ( 25 – 29 ). In addition, early-stage MF has been reported to progress in over 20% of patients within the first five years alone ( 30 ).…”

Section: Utility Of Immunosequencing In Skinmentioning

confidence: 99%

Immunosequencing applications in cutaneous T-cell lymphoma

Mandel,

Gleason,

Joffe

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Immunosequencing has emerged as a newer clinical test for assessment of T-cell clonality in the blood and skin of cutaneous T-cell lymphoma (CTCL) patients. Utilization of immunosequencing, also known as high-throughput sequencing of the T-cell receptor (HTS-TCR), enables identification and quantification of the precise genetic signature of dominant T-cell clones. Although immunosequencing is more sensitive than commonly used methods such as polymerase chain reaction (PCR) paired with capillary electrophoresis or flow cytometry, it remains underutilized for CTCL management. Nonetheless, incorporation of HTS-TCR in clinical practice offers distinct advantages compared to other molecular analyses that may improve diagnostic evaluation, prognostication, and disease monitoring in CTCL. The objective of this comprehensive review is to provide a thorough explanation of the application of immunosequencing in the context of CTCL. We describe the significance of T-cell clonality and the methods used to detect it, including a detailed comparison between PCR paired with capillary electrophoresis and HTS-TCR. The utilization of immunosequencing in the blood and skin of CTCL patients is discussed in depth, specifically outlining how HTS-TCR can assist in diagnosing CTCL, predicting outcomes, and tracking disease progression. Finally, we address the potential applications of immunosequencing in clinical management and research as well as the novel challenges it presents.

show abstract

Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review

Cited by 9 publications

References 58 publications

Mycosis Fungoides Presenting After Dupilumab Therapy: Case Report and Systematic Review

Mycosis Fungoides Presenting After Dupilumab Therapy: Case Report and Systematic Review

Advances in CAR-T-cell therapy in T-cell malignancies

Immunosequencing applications in cutaneous T-cell lymphoma

Contact Info

Product

Resources

About